Joridigi
If you read the report it is based on TA only and it mainly states that PRR is at a BULLISH. It does say it seems overbought, based on financial performance and comparison to other biotech revenue earners, etc. So please don't post inaccurately without reading the report properly. The report is based on statistics and does not consider Canvas, Nasdaq and other qualitative aspects.
prr report 24 feb 2012, page-6
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.5¢ | $469.8K | 1.579M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 297652 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 7500 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |